Terms: = Prostate cancer AND STAT3, FLJ20882, 6774, ENSG00000168610, APRF, P40763, MGC16063 AND Treatment
274 results:
1. Butyrate increases methylglyoxal production through regulation of the JAK2/stat3/Nrf2/Glo1 pathway in castration‑resistant prostate cancer cells.
Hsia YJ; Lin ZM; Zhang T; Chou TC
Oncol Rep; 2024 May; 51(5):. PubMed ID: 38577936
[TBL] [Abstract] [Full Text] [Related]
2. Curcumin Enhances the Anti-cancer Efficacy of CDK4/6 Inhibitors in prostate cancer.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
[TBL] [Abstract] [Full Text] [Related]
3. Leptin promotes proliferation of human undifferentiated spermatogonia by activating the PI3K/AKT/mTOR pathway.
Xin S; Xiaoxuan L; Yixuan Z; Zhikang C
Am J Reprod Immunol; 2024 Jan; 91(1):e13811. PubMed ID: 38282611
[TBL] [Abstract] [Full Text] [Related]
4. Novel two-tiered screening approach identifies synergistic combinations of natural compounds for prostate cancer prevention and treatment.
Friedman CA; Saha A; Lavender Hackman G; Lu X; Lodi A; Tiziani S; DiGiovanni J
Mol Carcinog; 2024 Apr; 63(4):589-600. PubMed ID: 38197430
[TBL] [Abstract] [Full Text] [Related]
5. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.
Kim S; Park JM; Park S; Jung E; Ko D; Park M; Seo J; Nam KD; Kang YK; Lee K; Farrand L; Kim YJ; Kim JY; Seo JH
J Exp Clin Cancer Res; 2023 Nov; 42(1):292. PubMed ID: 37924112
[TBL] [Abstract] [Full Text] [Related]
6. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway.
Mao F; Gao L; Liu L; Tang Y
J Chemother; 2024 May; 36(3):238-248. PubMed ID: 37916436
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
8. Dieckol prevents prostate cancer cell proliferation by transcriptionally attenuating JAK/stat3 signaling pathway.
Karuppaiya V; Annamalai A; Krishnamurthy S; Soundarapandian K
Environ Toxicol; 2024 Mar; 39(3):1187-1196. PubMed ID: 37886886
[TBL] [Abstract] [Full Text] [Related]
9. Network pharmacology and molecular docking to explore the mechanism of Sheng Xue Bao mixture against iron deficiency anemia.
Wang Y; Qinqin H; Wang H; Zhang H; Zhang X; Liu W; Xiang Z; Gu Y
Medicine (Baltimore); 2023 Sep; 102(37):e35012. PubMed ID: 37713882
[TBL] [Abstract] [Full Text] [Related]
10. stat3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J; Philippe C; Schlederer M; Atas E; Pecoraro M; Grund-Gröschke S; Li WJ; Tracz A; Heidegger I; Lagger S; Trachtová K; Oberhuber M; Heitzer E; Aksoy O; Neubauer HA; Wingelhofer B; Orlova A; Witzeneder N; Dillinger T; Redl E; Greiner G; D'Andrea D; Östman JR; Tangermann S; Hermanova I; Schäfer G; Sternberg F; Pohl EE; Sternberg C; Varady A; Horvath J; Stoiber D; Malcolm TI; Turner SD; Parkes EE; Hantusch B; Egger G; Rose-John S; Poli V; Jain S; Armstrong CWD; Hoermann G; Goffin V; Aberger F; Moriggl R; Carracedo A; McKinney C; Kennedy RD; Klocker H; Speicher MR; Tang DG; Moazzami AA; Heery DM; Hacker M; Kenner L
Mol Cancer; 2023 Aug; 22(1):133. PubMed ID: 37573301
[TBL] [Abstract] [Full Text] [Related]
11. Combination of Lycopene and Curcumin Synergistically Alleviates Testosterone-Propionate-Induced Benign Prostatic Hyperplasia in Sprague Dawley Rats via Modulating Inflammation and Proliferation.
Wang S; He W; Li W; Zhou JR; Du Z
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446563
[TBL] [Abstract] [Full Text] [Related]
12. Polysaccharides from Lentinus edodes prevent acquired drug resistance to docetaxel in prostate cancer cells by decreasing the TGF-β1 secretion of cancer-associated fibroblasts.
Zhang W; Tao N; Bai L
J Nat Med; 2023 Sep; 77(4):817-828. PubMed ID: 37354258
[TBL] [Abstract] [Full Text] [Related]
13. stat3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies.
Hashemi M; Abbaszadeh S; Rashidi M; Amini N; Talebi Anaraki K; Motahhary M; Khalilipouya E; Harif Nashtifani A; Shafiei S; Ramezani Farani M; Nabavi N; Salimimoghadam S; Aref AR; Raesi R; Taheriazam A; Entezari M; Zha W
Environ Res; 2023 Sep; 233():116458. PubMed ID: 37348629
[TBL] [Abstract] [Full Text] [Related]
14. Inducing apoptosis by using microRNA in radio-resistant prostate cancer: an in-silico study with an in-vitro validation.
Darvish L; Bahreyni-Toossi MT; Aghaee-Bakhtiari SH; Firouzjaei AA; Amraee A; Tarighatnia A; Azimian H
Mol Biol Rep; 2023 Jul; 50(7):6063-6074. PubMed ID: 37294470
[TBL] [Abstract] [Full Text] [Related]
15. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant prostate cancer Cells.
Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
[TBL] [Abstract] [Full Text] [Related]
16. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract] [Full Text] [Related]
17. The Feasibility and Value of a Focal Therapy Multidisciplinary Tumor Board, Including Radiographic and Pathological Overreads in Refining the Selection for High Intensity Focused Ultrasound in prostate cancer Patients.
Benidir T; Wood A; Lone Z; Schwen Z; Abouassaly R; Nguyen J; Olivares R; Weight CJ; Purysko AS
Urol Pract; 2023 Jul; 10(4):372-377. PubMed ID: 37103528
[TBL] [Abstract] [Full Text] [Related]
18. Deciphering stat3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance.
Hashemi M; Sabouni E; Rahmanian P; Entezari M; Mojtabavi M; Raei B; Zandieh MA; Behroozaghdam M; Mirzaei S; Hushmandi K; Nabavi N; Salimimoghadam S; Ren J; Rashidi M; Raesi R; Taheriazam A; Alexiou A; Papadakis M; Tan SC
Cell Mol Biol Lett; 2023 Apr; 28(1):33. PubMed ID: 37085753
[TBL] [Abstract] [Full Text] [Related]
19. LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and stat3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects.
Duprat F; Robles C; Castillo MP; Rivas Y; Mondaca M; Jara N; Roa F; Bertinat R; Toledo J; Paz C; González-Chavarría I
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982155
[TBL] [Abstract] [Full Text] [Related]
20. Role of Ganetespib, an HSP90 Inhibitor, in cancer Therapy: From Molecular Mechanisms to Clinical Practice.
Youssef ME; Cavalu S; Hasan AM; Yahya G; Abd-Eldayem MA; Saber S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902446
[TBL] [Abstract] [Full Text] [Related]
[Next]
